Back to Screener

Healthcare

Neuren Pharmaceuticals Limited(NURPF)

Live Price

Offline

$8.88

+0.00% today

1Y Change

-1.36%

Window

Jun 26, 2025 โ†’ Jun 18, 2026

Market Cap
$1.58B
Revenue Growth
-70.2%
EPS Growth
-78.0%
Dividend Yield
0.0%

Coverage: 251 bars ยท Jun 26, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Neuren Pharmaceuticals Limited (NURPF) is a Healthcare stock with a market cap of $1.58B and listed on OTC. The stock last traded around $8.88 and down 1.4% across the available one-year price window (Jun 26, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of -70.2%, EPS growth of -78.0%, a dividend yield of 0.0%. What stands out right now is revenue -70.2%, EPS -78.0%, free cash flow +1211.1% with operating margin 11.0% and ROIC 1.6%. Valuation already assumes a fairly strong business story at P/E 51.9 and price/sales 24.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NURPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

NURPF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

NURPF

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

NURPF Max Drawdown

-44.45%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for NURPF and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for NURPF

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.